Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
|Slideshows|February 25, 2015
Slide Show: Renal Cell Carcinoma
Author(s)OncoTherapy Network Staff
This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.
Advertisement
Advertisement
Related to this article
Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
3
SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit
4
Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma
5